勃林格殷格翰公布的数据显示，其药物Survodutide在临床试验中取得了显著效果，实现了内脏脂肪减少34%和肝脏脂肪减少63%，同时有效控制了瘦体重的流失。这一结果凸显了该药物在治疗与肥胖相关代谢疾病方面的潜力，可能为患者提供一种新的有效治疗方案。
勃林格殷格翰公布的数据显示，其药物Survodutide在临床试验中取得了显著效果，实现了内脏脂肪减少34%和肝脏脂肪减少63%，同时有效控制了瘦体重的流失。这一结果凸显了该药物在治疗与肥胖相关代谢疾病方面的潜力，可能为患者提供一种新的有效治疗方案。
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.